Abstract
. Introduction
investigate the regulation of NHE activity, experiments are 2 often performed in the absence of HCO in the medium, 3 In myocardium, as in other tissues, intracellular pH thereby rendering NBC inactive and making NHE the sole (pH ) affects numerous cellular processes and therefore acid extrusion pathway. i has to be tightly regulated. Under physiological conditions, In cardiac myocytes, the steep increase in sarcolemmal this regulation is achieved principally by the integrated NHE activity that occurs in response to lowering pH (i.e. 'acid extruders' and two 'acid loaders') that operate at low [2] . This indicates that more than one H ion binds to the 1 1 basal activity [1] . As pH drops, however, the Na / H NHE protein during the transport cycle, and has led to the i 1 2
exchanger (NHE) and the Na / HCO cotransporter suggestion that the NHE protein contains a non-transport- 3 1 (NBC) become progressively more active and extrude acid ing H -binding site, which regulates NHE activity. This is 2 from the cell. Conversely, as pH increases, the Cl / consistent with previous observations in other cells that the i 2 HCO exchanger (also known as the anion-exchanger activity of NHE isoform 1 (NHE1), which is the molecular 3 2 2 (AE)) and the Cl / OH exchanger (CHE) become actihomologue of the cardiac sarcolemmal NHE [3] , is reg-1 vated and effectively import acid. In studies designed to ulated through the interaction of intracellular H with an allosteric modifier site (sometimes referred to as the 'proton sensor') within the transmembrane domain of the exchanger [4, 5] . Thus, as pH falls, the proton sensor site that, in cardiac myocytes, sarcolemmal NHE activity is i becomes increasingly occupied and, through an allosteric subject to exquisite regulation by a variety of extracellular regulatory mechanism, leads to a greater increase in NHE stimuli, most of which act through G protein-coupled activity than would be expected from a simple increase in receptors (GPCRs). Intriguingly, although the majority of 1 the availability of transportable H ions. the GPCR systems that have been studied to date have In cardiac myocytes, the NHE1 protein appears to be been shown to stimulate sarcolemmal NHE activity, there localised predominantly to the intercalated disc region and is also evidence that some may inhibit NHE activity or its transverse-tubules [6] , although the functional significance stimulation through other pathways. of this distribution is not clear. The NHE1 protein is known to consist of a 500 amino acid transport domain that is located in the membrane and contains 12 trans-2 . GPCR-mediated stimulation of sarcolemmal NHE membrane-spanning segments, and a 300 amino acid activity regulatory domain that extends into the cytoplasm [7] . The proton sensor site is within the transport domain and Available evidence suggests that GPCR systems that are remains functional in the absence of the regulatory dolinked to heterotrimeric G proteins of the G subtype q main; nevertheless, the pH -sensitivity of the proton sensor (G PCRs) mediate an increase in sarcolemmal NHE i q (and therefore the maintenance of pH in the normal range) activity, through a change in the pH sensitivity of the relationship (similar to that depicted in Fig. 1 ), in response to a -AR stimulation [11] . Such an effect of a -AR 1 1 stimulation has been reported also in guinea-pig ventricular myocytes [12] . These studies provide strong evidence that a -AR stimulation leads to increased sarcolemmal NHE [24] . With respect to the cardiac myocyte, both thrombin angiotensin II was shown to increase resting pH through a and the synthetic thrombin receptor activating peptide i mechanism dependent on NHE activity, and to produce a SFLLRN have been shown to increase sarcolemmal NHE small but significant shift in the pH sensitivity of the activity [25] . The common ability of thrombin and i exchanger [16] . Grace et al. [17] showed that, in the SFLLRN to stimulate sarcolemmal NHE activity is con-1 perfused ferret heart, angiotensin II increased H efflux sistent with this action being mediated by the thrombin via the sarcolemmal NHE following an intracellular acid receptor that was first cloned by Vu et al. [26] , and is now load, and that this effect was inhibited by a selective known as protease-activated receptor 1 (PAR1). Indeed, antagonist of the angiotensin type 1 (AT ) receptor.
the mRNA for PAR1 is expressed in adult rat ventricular 1 However, in adult rat ventricular myocytes, angiotensin II myocytes [25] . Nevertheless, targeted disruption of the produced only a small (0.02 pH unit) increase in resting PAR1 gene in mice has revealed that additional thrombin pH , an effect that was absent in hypertrophied cells [18] .
receptors exist [27] and a second thrombin receptor, PAR3, i
More recently, we have reported that angiotensin II, when has been cloned and shown to be expressed in human used alone, had no significant effect on sarcolemmal NHE myocardium [28] . Furthermore, PAR2, a trypsin-activated activity in adult rat ventricular myocytes [19] . To the receptor that is activated also by SFLLRN, has been shown contrary, when given together with PD123319, a selective to be present in neonatal rat ventricular myocytes [29] . antagonist of the angiotensin type 2 (AT ) receptor, Therefore, at present, there is some uncertainty regarding 2 angiotensin II was able to stimulate sarcolemmal NHE the identity of the receptor(s) that mediate thrombin-inactivity in a concentration-dependent manner [19] . This duced stimulation of sarcolemmal NHE activity. effect of angiotensin II was abolished in the presence of the AT antagonist losartan, suggesting that activation of 2 . [19] . tion of sarcolemmal NHE activity by cholinergic stimuli. Thus, it appears that angiotensin II is capable of stimulatIn canine Purkinje fibres, the application of carbachol, an ing sarcolemmal NHE activity through the AT receptor, esterase-resistant cholinergic agonist, has been shown to 1 although the magnitude of the response may be modulated increase both resting pH and the rate at which pH i i by altered availability of angiotensin receptor subtypes, for recovered following an intracellular acid load [21] . These example as a consequence of disease, pharmacological effects were inhibited by both amiloride and atropine, manipulation or species difference.
suggesting that carbachol stimulates sarcolemmal NHE activity via muscarinic receptors. The identity of the 2 .3. Endothelin receptors muscarinic receptor subtype(s) that regulate sarcolemmal NHE activity remains unknown. Based on the observation Kramer et al. have shown that endothelin increases that, in many mammalian species, the predominant musresting pH in adult rat ventricular myocytes and that this carinic receptor in the heart is the M receptor [14], it is i 2 effect is blocked by NHE inhibition [20] . In subsequent likely that cholinergic stimulation of sarcolemmal NHE 1 work, endothelin has been shown to stimulate H efflux activity is mediated through this receptor. via the sarcolemmal NHE, following an intracellular acid load, in both canine cardiac Purkinje fibres [21] and rat 2 .6. Orphan receptors ventricular myocytes [18] . There is no direct evidence available on the identity of the receptor subtype that Although over 300 GPCRs have been identified through mediates the stimulation of sarcolemmal NHE activity by genomic research, the endogenous ligands for over 100 of endothelin. Nevertheless, the ET receptor is known to be these receptors are not yet known [30] . It is likely that A the predominant endothelin receptor subtype expressed in several of these 'orphan' receptors are expressed in the rat myocardium [22] and is therefore likely to be responcardiac myocyte, and that some of these may regulate sible for endothelin-induced stimulation of sarcolemmal sarcolemmal NHE activity and thereby cardiac function. NHE activity, at least in this species. Consistent with this Indeed, apelin, the endogenous ligand for the recently mechanism, in isolated rat hearts, pharmacological NHE 'de-orphanised' APJ receptor, has been shown to have a inhibition and a selective antagonist of the ET receptor positive inotropic effect in the adult rat heart [31]. The A have been shown to similarly attenuate the deleterious positive inotropic effect of apelin could be partially effects of endothelin during ischemia and reperfusion [23] .
blocked by pretreatment of hearts with the NHE inhibitors methylisobutylamiloride and zoniporide [31] , suggesting significant inhibition of NHE activity [19] . Therefore, it that APJ receptors stimulate sarcolemmal NHE activity.
appears that AT receptor activation may set in train 2 Nevertheless, such a role for APJ receptors remains to be intracellular processes that inhibit NHE-stimulatory sigconfirmed by direct measurements of NHE activity.
nalling, rather than inhibit NHE activity directly [19] . acid load, again in HCO -free solution [12] . In dog 4 . Distal signalling mechanisms Purkinje fibres, isoprenaline had no effect on resting pH , i but pH recovery from an intracellular acid load was again i
The intracellular regulatory domain of the NHE1 protein slowed, indicating reduced NHE activity [21] . In the same contains a number of potential phosphorylation sites [8] . study, pretreatment with atenolol was shown to abolish the Indeed, in non-myocyte cells, activation of several kinase negative effect of isoprenaline on pH recovery, confirming i pathways has been shown to produce an increase in NHE1 that the effect was mediated by the b -AR [21] . In view of 1 phosphorylation concomitantly with an increase in NHE these opposing effects of the principal myocardial postactivity [36, 37] . Phosphorylation-mediated stimulation of synaptic adrenergic receptors (i.e. a -and b -ARs), the net 1 1 NHE activity most likely arises from a conformational effect of the endogenous catecholamines noradrenaline and change that alters the interaction of the regulatory domain adrenaline on sarcolemmal NHE activity is likely to be 1 with the transport domain, resulting in increased H modulated by the relative density or functionality of these affinity of the proton sensor [4] . the AT -selective agonist CGP42112A) does not produce a kinases were identified as ERK and p90 (which is itself and PKC pathways, much less is known about the signalling mechanisms employed by GPCRs that either inhibit NHE activity (e.g. b -adrenergic receptors) or inhibit its stimulation by other GPCRs (e.g. adenosine A receptors). See text for details. AC, 1 1 RSK adenylate cyclase; ERK, extracellular signal-regulated kinase; PKC, protein kinase C; PLC, phospholipase C; RSK, p90 ribosomal S6 kinase (p90 ).
regulated by ERK-mediated phosphorylation [45] ) and contributions of direct phosphorylation of the NHE1 pharmacological inhibition of the ERK pathway was protein by ERK itself versus its downstream mediator RSK shown to abolish an endothelin-induced increase in resting p90 in GPCR-mediated stimulation of sarcolemmal pH . In our own work in adult rat ventricular myocytes, NHE activity.
i inhibiting a -AR-mediated activation of ERK, using Protein kinase C (PKC) also appears to play a critical 1A either PD98059 or UO126 (which are structurally-distinct role in the stimulation of sarcolemmal NHE activity by inhibitors of the ERK kinase MEK1 [46] ), was found to some GPCR agonists, on the basis of studies with a variety RSK inhibit both p90 activation and stimulation of sarcolemof pharmacological PKC inhibitors. Thus, agents such as mal NHE activity [47] . Importantly, MEK1 inhibition has GF109203X (also known as bisindolylmaleimide I) also been shown to inhibit the stimulation of sarcolemmal [19, 25, 47] , chelerythrine [25] , H-7 [11, 20] , staurosporine NHE activity via the angiotensin AT receptor [19] , as [21] and sphingosine [11, 20] have all been shown to 1 well as by non-GPCR-mediated stimuli [48] . These findinhibit the stimulation of sarcolemmal NHE activity, in RSK ings, which indicate that the ERK / p90 pathway plays a response to diverse stimuli such as a -AR agonists 1 critical role in the regulation of sarcolemmal NHE activity [11, 47] , angiotensin II [19] , thrombin [25] , endothelin [20] in cardiac myocytes, are consistent with earlier data that and carbachol [21] . Nevertheless, the regulatory domain of have shown reduced thrombin-induced stimulation of NHE1 has been shown not to be a substrate for in vitro NHE1 activity in non-myocyte cells that had been transphosphorylation by a mixture of PKC isoforms [38] , and fected with a dominant-negative ERK mutant [49] . Neverthe mechanism(s) through which PKC may regulate sartheless, further work is required to determine the relative colemmal NHE activity remain unclear. In response to some stimuli, such as activation of angiotensin AT kinase D, whose over-expression inhibits phorbol ester-1 receptors, PKC may stimulate sarcolemmal NHE activity induced stimulation of plasma membrane NHE activity in via the activation of the ERK pathway [19] . In contrast, other cell types [54] , may yield novel information in this PKC and ERK appear to mediate independent but necesarea. sary signalling pathways in the stimulation of NHE activity Although direct phosphorylation is likely to be an by a -AR agonists [47] .
important mechanism in GPCR-mediated regulation of 1 A major concern in the interpretation of data obtained sarcolemmal NHE activity, it should be noted that, in with PKC inhibitors is the suspect specificity of these non-myocyte cells, removal of the last 180 amino acids agents. In this regard, recent in vitro kinase assays have from the regulatory domain of NHE1 abolishes its phosrevealed that widely-used PKC inhibitors, such as the phorylation but only partially inhibits its stimulation by bisindolylmaleimides, also inhibit both p70 S6 kinase and thrombin [4, 55] . This suggests that mechanisms other than RSK p90 with similar potency [50, 51] . Any non-specific direct phosphorylation also contribute to the regulation of RSK inhibition of p90 by PKC inhibitors would be of NHE1 activity. Indeed, deletion experiments have sug- 21 particular concern in investigations of the signalling mechgested that the binding of Ca -calmodulin to the regulaanisms that regulate sarcolemmal NHE activity. This is tory domain increases NHE1 activity [5, 56, 57] . In contrast, RSK 21 because, as noted above, p90 is known to phosphorthe association of a Ca -binding calcineurin-homologous ylate the NHE1 protein [41] and is believed to play a key protein (CHP) with a separate site in the regulatory domain role in GPCR-mediated stimulation of sarcolemmal NHE has been suggested to inhibit NHE1 activation [58] , activity in cardiac myocytes [44, 47] . Thus, the possibility although more recent data suggest that CHP may instead exists that the ability of some PKC inhibitors to attenuate be an essential co-factor for NHE1 activity [59] . investigation is also required to determine the molecular which suggests a role for Ca -dependent signalling mechanisms through which PKC may regulate sarcolemmechanisms in cAMP-mediated regulation of the exmal NHE activity and to identify the PKC isoform(s) changer. involved.
Little is known about the distal signalling mechanisms through which some GPCRs attenuate sarcolemmal NHE 5 . Functional significance activity or its stimulation via other receptors. In dog Purkinje fibres, the NHE-inhibitory effect of b -AR stimu-
.1. Role in regulation of pH and contractility
1 i lation could be mimicked by the adenylate cyclase activator forskolin, or the phosphodiesterase inhibitors theoThe main function of the sarcolemmal NHE is to phylline and 3-isobutyl-1-methylxanthine (IBMX) [21] .
remove acid equivalents from the cell. Under physiological 2 IBMX has been shown to inhibit sarcolemmal NHE conditions (i.e. in the presence of HCO ), however, NBC 3 activity also in sheep Purkinje fibres [52] . These observaactivity also contributes to such acid extrusion [1] . Theretions suggest a role for the second messenger cyclic fore, the net effect of GPCR stimulation on the rate of acid adenosine monophosphate (cAMP) in the b -AR-mediated extrusion will depend on the responses of both NHE and 1 response, although the molecular mechanism(s) through NBC to the pertinent stimulus. There is only limited which cAMP may inhibit sarcolemmal NHE activity information available on GPCR-mediated regulation of remain unclear. A regulatory role for protein kinase A NBC activity. Lagadic-Gossmann et al. [12] have shown (PKA), which is activated by cAMP, is well established for that, in guinea-pig ventricular myocytes, adrenergic stimu-NHE isoform 3, but there are no consensus phosphorylalation has opposing effects on NHE versus NBC activity; tion sites for PKA in the regulatory domain of NHE1 and thus, a -AR stimulation was shown to activate NHE but 1 it is unlikely that direct phosphorylation of NHE1 by PKA inhibit NBC, while b -AR stimulation inhibited NHE but 1 occurs [53] . The molecular mechanism(s) through which activated NBC. In the same study, the net effect of the the counter-regulatory effects of GPCRs, such as the physiological adrenergic agonists noradrenaline and adangiotensin AT receptor [19] and the adenosine A renaline, which stimulate both a -and b -ARs, was to sarcolemmal NHE activity [19, 35] or the attenuation of contrast to the opposite effects of adrenergic stimulation on ERK activation [19] . Investigation of the role of protein NHE versus NBC activity, recent evidence suggests that AT receptor stimulation by angiotensin II increases velopment that is observed in response to myocardial 1 sarcolemmal NBC activity [60] , as it does sarcolemmal stretch has also been shown to be sensitive to inhibition by NHE activity [19] . In the case of NBC, however, the AT NHE inhibitors [69] . There is recent evidence that this 1 receptor-mediated response does not appear to be subject slow force response occurs through autocrine / paracrine to counter-regulation via the AT receptor [60] [61, 62] . Clearly, the sustained effect of any Since the late 1980s, substantial evidence has accumugiven stimulus on pH will be determined by its net effect lated that increased activity of the sarcolemmal NHE i on acid equivalent flux across the sarcolemma, as decontributes to the development of myocardial injury and termined by the sum of its actions on inward or outward dysfunction during ischaemia and reperfusion [71, 72] . flux through all four pH-regulatory transporters. NevertheIndeed, selective NHE inhibitors have been shown to be less, as proposed by Leem et al. [1] , a GPCR-mediated cardioprotective in this setting in numerous animal studies change in the pH sensitivity (and therefore the activity) of (see reviews by Avkiran [73] and Karmazyn et al. [74] ).
i an individual transporter, such as the sarcolemmal NHE, Importantly, recent data suggest that NHE inhibition may can produce a displacement of pH within a permissive provide cardioprotective benefit in high-risk patients who i range (pH 6.95-7.25 in the guinea pig ventricular undergo global myocardial ischaemia and reperfusion i myocyte), with functional consequences. during coronary artery bypass graft surgery [75] , an A GPCR-mediated increase in sarcolemmal NHE activiobservation which awaits confirmation by current clinical ty would of course produce not only an increased rate of trials [76] . acid extrusion (and thereby relative intracellular alkalinizaIt is well-established that myocardial ischaemia results 1 tion) but also an increased rate of Na influx into the in activation of the sympathetic nervous system, as well as cardiac myocyte. Each of these processes can have a the local release of noradrenaline within the ischaemic significant impact on myocardial contractility, through zone [77] . This appears to be accompanied by enhanced distinct mechanisms. Altered pH can regulate contractility a -adrenergic signalling, through increased receptor den-
at almost every stage of excitation-contraction coupling, sity and enhanced receptor coupling to distal steps in the with intracellular alkalosis producing a positive inotropic relevant signalling cascade [78] . It is likely therefore that effect that is mediated largely through increased myofilaa -AR stimulation may play an important role in regulat- 1 21 ment Ca responsiveness (see review by Orchard and ing sarcolemmal NHE activity during ischaemia. In this Kentish [63] ). In parallel with this, any increase in the context, it is important to note that a -AR stimulation
intracellular Na concentration ( [Na ] ) that may arise appears to retain its ability to increase sarcolemmal NHE i 1 from increased Na influx via the sarcolemmal NHE can activity even in the presence of extracellular acidosis, also produce a positive inotropic effect, principally through which accompanies myocardial ischaemia [79] . Further- [20, 67] have been shown to tion [80] . In our own laboratory, we have shown that, in rat produce positive inotropic responses that are attenuated by hearts subjected to regional ischaemia, a -AR stimulation 1 inhibition of the sarcolemmal NHE. Interestingly, the within the ischaemic zone exacerbates reperfusion-induced positive inotropic effect of a -AR stimulation is attenuated arrhythmias, and that this pro-arrhythmic effect is 1 also by stimulation of the adenosine A receptor [68] , in a abolished not only by a -AR blockade but also by NHE 1 1 A manner that mirrors the inhibitory effect of this receptor on inhibition [81] . These data support the possibility that a -AR-mediated stimulation of sarcolemmal NHE activity a -AR-mediated stimulation of sarcolemmal NHE activity 1 1 [35]. These data suggest that GPCR-mediated regulation of influences the outcome of myocardial ischaemia and sarcolemmal NHE activity makes an important contribureperfusion. It should be noted, however, that during tion to the inotropic responses that are produced by a myocardial ischaemia in vivo, simultaneous stimulation of variety of neurohormonal stimuli; nevertheless, the relative b -ARs by endogenous catecholamines may offset the 1 contributions of altered pH (and thereby myofilament effects of a -AR stimulation on sarcolemmal NHE activi-
Ca responsiveness) versus altered [Na ] (and thereby ty. Other GPCR-mediated stimuli that alter sarcolemmal i each case. Interestingly, the slow increase in force de-NHE activity are also likely to be of pathophysiological importance during myocardial ischaemia and reperfusion. recently to require NHE activity, on the basis that the Intracoronary thrombosis, the commonest cause of acute hypertrophic phenotype was almost completely abolished myocardial ischaemia in man [82] , is associated with by chronic treatment with the NHE inhibitor cariporide elevated levels of thrombin in the vicinity of the evolving [96] . These observations raise the possibility that NHE thrombus [83] . Thus, thrombin may increase sarcolemmal activity may play a permissive role in the development of NHE activity through the stimulation of its cognate cardiac hypertrophy, such that in the absence of such receptors on neighbouring myocytes. Indeed, thrombin activity (i.e. in the presence of NHE inhibitors) the 1 receptor stimulation exacerbates the increase in [Na ] that phenotype is attenuated regardless of the nature of the i occurs during ischaemia [84] , although the role of NHE hypertrophic stimulus. This is consistent with increasing activity in mediating this response has not been deterevidence that NHE inhibitors suppress the development of mined. Nevertheless, there is preliminary evidence that hypertrophy in a diverse range of in vitro and in vivo thrombin induces a potent pro-arrhythmic effect during models. Thus, in recent studies, NHE inhibitors have been regional ischaemia and reperfusion in the rat heart, by a shown to attenuate stretch-induced hypertrophy of cultured mechanism that is blocked by NHE inhibition [85] .
neonatal rat ventricular myocytes in vitro [97] , postEndothelin is also released during myocardial ischaemia myocardial infarction myocardial hypertrophy in rats in and reperfusion [86] , and may lead to the stimulation of vivo [98] [99] [100] [101] , and myocardial hypertrophy in response to sarcolemmal NHE activity. Certainly, exposure of hearts to left [102] or right [103] ventricular pressure overload in exogenous endothelin during ischaemia has been shown to rats in vivo. It appears therefore that, at least in the rodent depress the post-ischaemic recovery of contractile funcheart, NHE activity plays a fundamental role in the tion, an effect which could be blocked by NHE inhibitors induction and evolution of myocardial hypertrophy. Never- [23, 87] .
theless, the relative importance of increased (cf. mainIn view of the apparent detrimental effects of some tained) sarcolemmal NHE activity, as occurs in response to GPCR-mediated stimuli that increase sarcolemmal NHE G PCR stimulation, and the molecular mechanism(s) q activity, it is tempting to speculate that other GPCR through which NHE activity may regulate myocardial systems that suppress NHE activity may have the opposite hypertrophy remain to be elucidated. effect and afford myocardial protection during ischaemia and reperfusion. Consistent with this, there is evidence that cardiac-specific overexpression of the adenosine A re-1 6 . Conclusion ceptor in transgenic mice preserves myocardial integrity and function following regional ischaemia and reperfusion GPCR-mediated regulation of sarcolemmal NHE activi- [88] ; nevertheless, whether this effect is mediated through ty is likely to play significant roles in modulating myocara reduced sarcolemmal NHE activity is not known. dial function in both physiological and pathophysiological conditions. Greater understanding of the molecular sig-5 .3. Role in myocardial hypertrophy nalling pathways that mediate the stimulatory or inhibitory effects of various GPCR systems on sarcolemmal NHE There is substantial evidence that G PCR signaling q activity requires further investigation, and may ultimately pathways contribute significantly to the development of lead to the development of novel approaches for therapeucardiac hypertrophy, as well as its decompensation that can tic manipulation of these pathways. lead to heart failure [89] . In in vitro studies, many G PCR q agonists that stimulate sarcolemmal NHE activity (e.g. a -AR agonists, endothelin, angiotensin II, thrombin; see 1 A cknowledgements earlier) have been shown also to induce myocyte hypertrophy [90] [91] [92] [93] . This raises the possibility that the The authors' work is supported by the British Heart association between the stimulation of NHE activity and Foundation (BS / 93002; FS / 02 / 001), the Medical Rethe induction of hypertrophy may be of a causal nature, search Council, The Dunhill Medical Trust and the Charitwhich is consistent with recent data obtained with NHE able Foundation of Guy's and St Thomas' Hospitals. inhibitors. Thus, the hypertrophic response of adult rat ventricular myocytes to adrenergic stimulation has been shown to be attenuated by NHE inhibition [94, 95] . Intrigu-R eferences ingly, NHE inhibition attenuated the hypertrophic responses to the sustained (24 h) stimulation of either a - 
